Medivir AB (STO:MVIR), a research-based pharmaceutical company with a focus on oncology, announced on Friday that it has appointed Christina Herder as executive vice president, Strategic Business Development, effective 14 December 2017.

In her new role, Herder will report to CEO Christine Lind and will join Medivir's executive management team.

According to Medivir, the addition of Herder fills an important role focusing in the near-term on out-licensing of Medivir's projects that could benefit from the capabilities of a partner, whether at late stages of clinical development or early stages of research. Herder will also be responsible for leading any in-licensing or acquisition of projects that are synergistic with Medivir's scientific areas of expertise, as well as managing alliances with existing partners.

Most recently, Herder was CEO of Modus Therapeutics. Prior to Modus, she held various leadership positions at Sobi AB (and previously Biovitrum), including those in Corporate Development, Licensing and Portfolio and Project Management. She began her career at Pharmacia & Upjohn.